China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Moved Down to “Sell” by Wall Street Zen

Wall Street Zen downgraded shares of China SXT Pharmaceuticals (NASDAQ:SXTC) from a hold rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings downgraded shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, November 9th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Stock Performance

Shares of SXTC traded up $0.27 during midday trading on Friday, hitting $3.00. The stock had a trading volume of 225,037 shares, compared to its average volume of 431,397. The stock’s 50 day moving average is $114.33 and its 200 day moving average is $10,872.08. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. China SXT Pharmaceuticals has a 1 year low of $2.71 and a 1 year high of $8,375,880.00.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the development, manufacture and sale of traditional Chinese medicine (TCM) products. The company produces herbal formulations intended for use in the treatment and management of various health conditions, as well as products positioned for general wellness and health maintenance. Its product portfolio includes prescription medicines, over-the-counter medicines and dietary supplements. The company’s offerings are based on traditional Chinese medicinal practices and may be provided in forms such as herbal extracts, pills and other finished formulations.